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Summary Antigenic modulation of major histocompatibility and tumour associated antigens was observed in
neoplastic cells obtained from patients with pleural and abdominal effusions of breast and ovary carcinomas
following a single intracavitary dose of 18 x 106U recombinant IFN-a. This regimen resulted in antigenic
modulation in seven out of 11 tested cases, suggesting a potential, although limited, responsiveness of at least
a fraction of breast and ovary carcinoma cells to in situ biomodification with IFN-a.
Clinical trials with IFN-a have shown that the use of this
biomodifier is justified only in the treatment of a limited
number of hematologic malignancies, still remaining of little
use in the control of solid tumors (Goldstein & Laszlo, 1986).
To test the hypothesis that a low therapeutic efficacy of
IFN-o in the treatment of solid tumours might be related to
its inability in eliciting cellular responses, it would be
desirable to develop protocols capable of quantitatively ap-
preciating objective biological changes in neoplastic cells
exposed in vivo to IFN-a. Testing of antigenic modulation
may provide, in this context, an objective and quantitative
estimate of a cellular response. Being independent of the
clinical performance of the IFNs, antigenic modulation may
contribute to discriminate inappropriate delivery of biological
stimuli to cancer cells from other possible causes of thera-
peutic failure (Gamliel et al., 1990).
In the present report, surface expression of 11 independent
major histocompatibility complex (MHC) and tumour associ-
ated antigens (TAAs), has been assessed prior to and follow-
ing IFN-a administration, in a panel of 11 patients with
neoplastic cell effusions from breast or ovary cancer, previ-
ously selected for treatment with a single intracavitary dose
of recombinant IFN-a.
Because these cells are collected routinely and with
minimal risk for diagnostic and therapeutic purposes, this
protocol overcomes, at least in part, the ethically ques-
tionable procedure of repeated bioptic sampling of solid
tumours.
Materials and methods
Patients and clinical samples
Patients (three letter code) with breast (seven cases) and
ovary (four cases) carcinoma had been free of chemotherapy
for at least 1 month before IFN-ac administration. They were
treated with a single intracavity dose of 18 x 106 U IFN-a2
(Roche, Nutley, NJ). All patients gave their written consent.
Neoplastic effusions (20-40 ml) were obtained from the
pleural or abdominal cavity just prior to and 24 h after
IFN-a administration. Neoplastic cells were isolated from
erythrocytes and white blood cells by fractionation on a
density gradient, made up by diluting one volume of Percoll
(Pharmacia, Uppsala, Sweden) stock solution with two
volumes of cell suspensions in Phosphate (0.01 M) buffered
(pH 7.0) saline (0.9%) and subsequent centrifugation at 150g
for 30 min at room temperature.
Cell surface ELISA binding assay
Neoplastic cells were resuspended at 1 x 106ml1' in Lym-
phostabil (Biotest AG, Frankfurt, Germany), and stored at
4°C for 22-48 h (pretreatment samples) or 2-24 h (post
treatment samples). These storage procedures did not
significantly alter antigen expression, as comparatively
assessed by control ELISA testing ofcells isolated at 24-48 h
intervals from patients not treated with IFN-a (four cases).
This method of testing was found to be superior to separate
testing of pre- and post-treatment samples with internal
reference controls. At the end of the storage period, cells
from pre- and post-treatment samples were tested by an
ELISA assay, as described previously (Giacomini et al.,
1990).
Although general agreement exists that a 24 h IFN-a treat-
ment is capable of inducing only a suboptimal antigenic
modulation of most surface antigens (Greiner et al., 1985;
Giacomini et al., 1990 and 1991), longer intervals between
IFN-. administration and testing of antigenic modulation
were not considered, since IFN-o has a relatively short
(3-6 h) halflife in the bloodstream (Goldstein & Laszlo,
1986), and causes a readily reversible upregulation of class I
MHC antigens in in vivo exposed perypheral blood mono-
nuclear cells (Giacomini et al., 1991). In addition, the time
interval between pre- and post-treatment sample collections
was kept to a minimum in order to test antigen expression
after limited periods of neoplastic cell storage at 4°C.
Results
Antigenic modulation by IFN-cz
Out of a total of 24 cases collected, only 11 could be
evaluated by ELISA because of poor viability and/or con-
tamination of neoplastic cells with leukocytes present in the
effusions. Out of the 11 testable cases, four resulted unre-
sponsive. Significant modulation of at least one antigen was
observed in the remaining seven cases (Figure 1). The fre-
quency of antigen upregulation was as follows: cyt-MAA
(three out of four tested samples) >class I MHC (five out of
seven) >Oc 125 and HFMG-2 (two out of the three cases
expressing significant levels of these determinants) >antigen
identified by MAb B1.l (two out of six) > antigens identified
by MAb B6.2 (one out of five) and B72.3 (one out of six).
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The antigens recognised by MAb 345 and Mov 19, on the
other hand, the former known to be only marginally, if at all,
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Figure I ELISA testing of IFN-a induced antigenic modulation.
Neoplastic cells from pleural and abdominal effusions of patients
(three letter code) with breast a, and ovarian b, carcinoma,
respectively, were obtained prior to 0, and following U, intra-
cavitary injection of IFN-a, and tested for the expression of
MHC, Breast (Br), Ovarian (Ov) and Melanoma (Mel) associated
antigens, as indicated, in an ELISA assay, using specific MAbs,
or spent media from the P3 x 63/NS1 cell line (-) as control.
OD492 nm readings ± ranges of duplicates are indicated. NT = not
tested.
controls for binding equalisation between pre- and post-
treatment samples. It should be noted that antigenic modula-
tion was unexpectedly detected in the case ofantigens such as
HMFG-2 and Oc 125, for which evidence of susceptibility to
IFN-x upregulation is not available (see Table I). No signifi-
cant differences were noted in the clinical outcome between
the seven patients moderately responsive to IFN-o antigenic
modulation and the four which were not.
Discussion
Only a few studies have so far documented changes in the
expression of cellular antigens induced in vivo by IFN-a in
neoplastic patients (Gamliel et al., 1990; Schiller et al., 1990;
Giacomini et al., 1991), and only one of these studies, based
on a regimen of intracavitary infusion very similar to that
herein described (except for the use of IFN-'y instead of
IFN-a), addressed this issue directly in neoplastic cells
(Allavena et al., 1990).
In spite of this relative paucity ofdata, it is becoming quite
clear that antigenic modulation does indeed occur in vivo.
However, it remains to be proven whether a poor or absent
response of tumour cells in situ to one or several of the
biological effects of the IFNs may represent a major
mechanism impairing their therapeutic efficacy. Our data
demonstrate that a significant upregulation of one or more
membrane antigens occurs in a consistent fraction of breast
and ovary carcinoma cells treated in vivo with IFN-o. By
taking advantage of a quantitative ELISA assay, we show
that the number of interferon susceptible antigens upregu-
lated in different cell samples and the entity of such upregula-
tion were, on the average, low. In addition, no antigen was
modulated in all samples.
The use of a single intracavitary dose of IFN-o does not
allow to draw unequivocal conclusions, since an insufficient
dosage or too short exposure to IFN-a of neoplastic cells
may affect the entity ofantigenic modulation. However, these
results are likely to reflect, at least in part, a true impairment
in the in vivo response ofneoplastic cells. This is suggested by
the observations that a 24 h in vitro treatment with IFN-.x is
efficient in eliciting at least suboptimal antigenic modulation
on three distinct breast carcinoma associated antigens recog-
nised by MAbs Bl.l, B72.3 and B6.2 (Greiner et al., 1985),
while the presently used protocol was quite inefficient in
inducing similar changes in vivo, even in effusions susceptible
to upregulation of class I MHC and/or other tumour anti-
gens. Therefore, our data are consistent with the hypothesis
that an inappropriate protocol of IFN-a administration, on
one hand, and a number of in vivo occurring inhibitory
influences, on the other, may adversely affect the potential
therapeutic and/or modulatory abilities of IFN-x in a percent-
age of breast and ovary carcinoma cells and/or antigens.
Among these inhibitory influences, a poor availability of
exogenous IFN-x at certain anatomical sites, the presence of
local inhibitory factors, and/or in situ production of antagon-
istic cytokines are all likely candidates.
Table I Specificity of monoclonal antibodies
Antigen Upregulation MW
MAb specificity by IFN-aa (Kd) Refs.
W6/32 class I MHC + + 44 + 12 Brodsky et al., 1979
KUL/05 class II MHC +/- 34 + 32 Giacomini et al., 1989
BlI. CEA-like + 160-180 Greiner et al., 1985
B6.2 glycoprotein + 90 Greiner et al., 1985
B72.3 glycoprotein + > 1000 Greiner et al., 1985
MBR I glycolipid Canevari et al., 1983 HMFG-2 Milk fat globules - 220 Griffith et al., 1987
OC 125 Ca 125 glycoprotein - 500 Bast et al., 1981
345.134S Differentiation Ag +/- 85 + 30 Giacomini et al., 1990
465.12S Cyt-MAA Prolif. epithelia + + (94) + 75 + 70 + (20)b Giacomini et al., 1990
' )Denotes either absence of specific literature or unresponsiveness to IFN-x. bNumbers in brackets refer
to components expressed only in certain cell lines. The cytoplasmic MAA may be expressed on the cell
surface in most cell lines. This fraction is measured in the present study.344 P. GIACOMINI et al.
Even in the lack of more detailed informations about the
type and relevance of the factors underlying this low re-
sponse, the present results demonstrate that tumour cells can
be modified by IFN-a in vivo. Thus, they extend to an
IFN-a/neoplastic effusion model previous observations in
other systems (Gamliel et al., 1990; Schiller et al., 1990;
Allavena et al., 1990; Giacomini et al., 1991), and rule out
the possibility of a state of absolute refractoriness of cancer
cells to in vivo biomodification with the IFNs.
Clearly, a correlation between antigenic modulation and
therapeutic efficacy of IFN-x could not be established on the
basis of the present data. This, however, was not the main
purpose of our testing, since the function of most tumour
associated antigens is unknown, and probably unrelated to
the induction of antitumour effects by the IFNs. For this
reason, the identification of markers of clinical response to
the IFNs will likely require the development of ad hoc
reagents.
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